Telithromycin

Annals of Internal Medicine

Volumn 144, Issue 6, 2006, Pages 447-448

  Turner, Michelle ^a,d   Corey, G Ralph ^b   Abrutyn, Elias ^c  

^a Campbell University   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A4; KETOCONAZOLE; KETOLIDE; MACROLIDE; PIMOZIDE; RIFAMPICIN; TELITHROMYCIN; ANTIINFECTIVE AGENT; PROTEIN SYNTHESIS INHIBITOR;

BLURRED VISION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIPLOPIA; DRUG ACTIVITY; DRUG BINDING; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; EDITORIAL; HUMAN; IN VITRO STUDY; LIVER FAILURE; NAUSEA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINUSITIS; TREATMENT DURATION; VISUAL DISORDER; NOTE; TOXIC HEPATITIS;

ANTI-BACTERIAL AGENTS; HEPATITIS, TOXIC; HUMANS; KETOLIDES; PROTEIN SYNTHESIS INHIBITORS;

EID: 33645648998     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-6-200603210-00014     Document Type: Editorial

References (20)

1. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP III, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144:415-20.
2. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18:621-49.
3. Product Information: Ketek [Telithromycin]. Kansas City, MO: Aventis Pharmaceuticals Inc.; October 2005.
4. Novotny GW, Jakobsen L, Andersen NM, Poehlsgaard J, Douthwaite S. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob Agents Chemother. 2004;48:3677-83.
5. Low DE, Felmingham D, Brown SD, Rangaraju M, Nusrat R. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J Infect. 2004;49:115-25.
6. Walsh F, Carnegy F, Willcock J, Amyes S. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother. 2004;53:793-6.
7. Hammerschlag MR, Roblin PM, Bebear CM. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother. 2001;48 Suppl T1:25-31.
8. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44:915-34.
9. Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy. 2005;51:339-46.
10. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002;30:378-86.
11. Van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin. 2002;18:397-400.
12. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract. 2003;57:377-84.
13. Roos K, Brunswig-Pitschner C, Kostrica R, Pietola M, Leroy B, Rangaraju M, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy. 2002;48:100-8.
14. Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J. 2003;82:576-80, 82-4, 586 passim.
15. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol. 2003;17:369-77.
16. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002;96:862-71.
17. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res. 2003;31:157-69.
18. Ketek FDA briefing document. Kansas City, MO: Aventis Pharmaceuticals Inc.; January 2003.
19. Nieman RB, Sharma K, Edelberg H, Caffe SE. Telithromycin and myasthenia gravis [Letter]. Clin Infect Dis. 2003;37:1579.
20. Aventis Pharmaceuticals Inc. Ketek worldwide experience. Updated August 2005. Accessed at www.ketek.com/hcp/WorldwideExperience.do on 8 February 2006.